Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationLeasesMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)
Ratios

China SXT Pharmaceuticals (SXTC) Other Gross PP&E Adjustments (2018 - 2025)

Historic Other Gross PP&E Adjustments for China SXT Pharmaceuticals (SXTC) over the last 8 years, with Q1 2025 value amounting to $2.2 million.

  • China SXT Pharmaceuticals' Other Gross PP&E Adjustments fell 111.84% to $2.2 million in Q1 2025 from the same period last year, while for Mar 2025 it was $2.2 million, marking a year-over-year decrease of 111.84%. This contributed to the annual value of $2.2 million for FY2025, which is 111.84% down from last year.
  • Latest data reveals that China SXT Pharmaceuticals reported Other Gross PP&E Adjustments of $2.2 million as of Q1 2025, which was down 111.84% from $2.3 million recorded in Q1 2024.
  • In the past 5 years, China SXT Pharmaceuticals' Other Gross PP&E Adjustments ranged from a high of $2.7 million in Q1 2022 and a low of $1.9 million during Q1 2023
  • For the 5-year period, China SXT Pharmaceuticals' Other Gross PP&E Adjustments averaged around $2.3 million, with its median value being $2.3 million (2024).
  • In the last 5 years, China SXT Pharmaceuticals' Other Gross PP&E Adjustments crashed by 2916.78% in 2023 and then skyrocketed by 1865.03% in 2024.
  • China SXT Pharmaceuticals' Other Gross PP&E Adjustments (Quarter) stood at $2.5 million in 2021, then grew by 5.96% to $2.7 million in 2022, then fell by 29.17% to $1.9 million in 2023, then grew by 18.65% to $2.3 million in 2024, then dropped by 1.12% to $2.2 million in 2025.
  • Its Other Gross PP&E Adjustments was $2.2 million in Q1 2025, compared to $2.3 million in Q1 2024 and $1.9 million in Q1 2023.